Eficacia y seguridad de IdegLira para la intensificación del tratamiento en la diabetes tipo 2

Costa Gil, José E; Faingold, María C; Fuente, Graciela V; Litwak, León E; Rodríguez, Martín.
Medicina (B.Aires) ; 78(4): 225-233, ago. 2018. graf, tab
Artículo en Español | LILACS | ID: biblio-954988

Documentos relacionados

  1. [Efficacy and safety of IdegLira for the intensification of type 2 diabetes treatment].
  2. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
  3. Liraglutide in Children and Adolescents with Type 2 Diabetes.
  4. Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.
  5. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
  6. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
  7. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
  8. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
  9. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
  10. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.